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INTRODUCTION
Transurethral resection of the prostate (TURP) is consid-
ered the standard treatment for men with benign prostatic
hyperplasia (BPH) (1). However, this procedure is associated
with significant morbidity. In order to minimize the periop-
erative morbidity of TURP procedures, various minimally
invasive alternatives have been introduced into clinical practice.
The high-power potassium titanyl phosphate (KTP) photo-
selective laser vaporization of the prostate (PVP) is emerg-
ing as a popular technology. Vaporization of the prostate with
an 80 W KTP laser combines the tissue-debulking proper-
ties of the TURP with the desirable hemostatic properties
of laser procedures (2). 
The complete resection of the prostate is the goal of TURP
procedures. However, a considerable volume of the prostate
may remain despite endoscopic appearances, after complete
resection of an adenoma (3). Chen et al. (4) reported that a
better clinical result after a TURP correlated significantly
with the completeness of the resection of the obstructing
adenoma. The impact of the vaporized volume after a PVP
has not been systematically investigated. In the present study,
we estimated the volume of the prostate that were vaporized
after a PVP and determined their impact on the clinical out-
comes in men with lower urinary tract symptoms/BPH. 
MATERIALS AND METHODS
Approval for this study was obtained from the Institution-
al Review Board of the Seoul National University Hospital.
The clinical records of 65 men, with a mean age of 67.7 yr
(range 53 to 85), who underwent PVP were retrospectively
reviewed. Inclusion and exclusion criteria, for the operative
technique, have been reported previously (5). Patients were
evaluated before the PVP by the International Prostate Symp-
tom Score (IPSS), quality of life (QOL) index, maximum flow
rate (Qmax), post-void residual (PVR), prostate volume, and
serum prostate-specific antigen (PSA) levels. In patients with
elevated PSA or a digital examination suspicious of prostate
cancer, prostate biopsy was performed to document the absence
of prostate cancer. If biopsies were negative for cancer, the
patients were included in this study. 
To ensure that the vaporized volume calculated was accu-
rate, pilot testing was conducted on 10 patients who under-
went TURP procedures (n=9) or an open prostatectomy (n=
1). Immediately before and after the surgery, in the operat-
ing room, the prostate volume was measured by transrectal
ultrasonography (TRUS) using the prolate ellipse formula
(6). The prostate tissue collected at resection was weighed
and the value was then recorded. The calculated volume of
the resected tissue was determined by the formula: calculat-
ed resected volume=pre-operative volume-post-operative vol-
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The One Year Outcome after KTP Laser Vaporization of the Prostate
According to the Calculated Vaporized Volume 
The aim of this study was to develop a new simple method for measuring the vapor-
ized volume and to evaluate the outcome of high-power potassium-titanyl-phos-
phate (KTP) photoselective laser vaporization. A total of 65 patients, with a mean
age of 67.7 yr (range 53 to 85), were included in the primary analysis. The vapor-
ized volume was calculated as the pre-operative volume minus the immediate post-
operative volume plus the volume of the defect. For all patients, the subjective and
objective parameters improved significantly after surgery. Six and 12 months after
surgery, the group with a smaller vaporized volume (<15 g) had a lower reduction
of the mean International Prostate Symptom Score (P=0.006 and P=0.004) and
quality of life index (P=0.006 and P=0.004) when compared to the group with a
greater vaporized volume (≥15 g). There were no differences in the change of the
maximum flow rate and post-void residual based on the vaporized volume. Our find-
ings suggest that the subjective improvement, after a high-power KTP laser vapor-
ization, may be dependent on the vaporized volume obtained after the procedure. 
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ume+volume of the defect. The defected volume was esti-
mated using the prostate volume calculation. We confirmed
that there was a significant correlation between the actual
weight of the surgical specimen and the estimated volume
of the resected tissue (r=0.970, P<0.001). Then, the vapor-
ized volume was estimated in 65 patients who underwent a
PVP using the same method and the same formula (Fig. 1).
All TRUS were performed by a single radiologist.
Follow-up was carried out at 1, 3, 6, and 12 months. At each
visit, the IPSS was recorded; in addition, Qmax and PVR were
recorded at 3, 6, and 12 months postoperatively. The prostate
volume was measured at 6 months postoperatively. The pri-
mary outcome measure was the change in subjective symp-
toms. The Qmax and PVR were secondary outcome measures.
For the statistical analysis, the patients were stratified into
two groups according to the median value at the cutoff of
14.8 g for vaporized volume; the vaporized volume was clas-
sified as <15 g (n=32) and ≥15 g (n=33). A comparison
between the groups was conducted using the Student’s t test
for the continuous data and the Armitage test for the cate-
gorical data. A 5% level of significance was adopted for all
statistical testing, and all statistical tests were two-sided. Sta-
tistical analysis was performed using a commercially avail-
able data analysis program, Statistical Package for Social Sci-
ences, version 13.0 (SPSS, Chicago, IL, U.S.A.). 
RESULTS
The baseline patient characteristics are shown in Table 1.
The prostate volume were greater in the group with more
vaporized volume (P<0.001). The patients with a greater
vaporized volume had a higher baseline PVR (P=0.001). The
PVP procedure was slightly faster in the group with a lower
vaporized volume when compared to those with a greater
vaporized volume (P=0.019). The total mean energy deliv-
ery for the two groups was 165.6 and 204.0 kJ, for the lower
and greater volume vaporization, respectively (P=0.020). No
statistical differences were observed regarding the other param-
eters evaluated. 
No severe intraoperative complication was observed. Mild
hematuria was identified in 18 patients (27.7%), which did
not require medical attention. One patient (1.5%) experienced
clot retention postoperatively and had catheter successfully
Fig. 1. Calculated vaporized volume was determined by the formula: vaporized volume=pre-operative volume-immediate post-operative
volume+defected volume. (A) transverse view (preoperative). (B) sagittal view (preoperative). (C) transverse view (postoperative). (D) sagittal
view (postoperative). Arrows indicate vaporized volume immediately after photoselective vaporization of the prostate. Calculated vapor-
ized volume was 18.7 mL (50-37+5.7). True vaporized volume was not checkable. 
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removed after 2 weeks. Postoperative transient urinary tract
irritation including urgency was experienced by 2 patients
(3.1%), which resolved without medical intervention. Acute
epididymitis was seen after the surgery in 1 patients (1.5%)
and a postoperative urethral stricture was observed in 1 (1.5%).
No blood transfusions were required and no other perioper-
ative complications were noted.
As the baseline prostate volume increased, the calculated
vaporized volume increased (r=0.709, P<0.001). The increased
values were observed at the time of the surgery (r=0.447, P<
0.001) and the energy delivered increased (r=0.381, P=0.002)
as the calculated vaporized volume increased (data not shown). 
The one year outcome data are shown in Figs. 2, 3. In each
group, an immediate and highly significant improvement
of the subjective and objective outcomes was evident. After
treatment, no statistical difference in the IPSS and the QOL
index was observed between the groups at the early follow-
up of three months; however, subjective improvements were
significantly higher in the group with a greater vaporized
volume (P<0.05) (Fig. 2). During the follow-up period, the
degree of improvement of the Qmax was similar in both groups.
There was no statistical difference in the PVR observed bet-
ween the groups after three months of follow up; however, the
Parameters
P
value
Vaporized volume
<15 grams ≥15 grams
Age (yr) 67.5±1.2 68.0±1.3 0.785
Prostate volume (mL) 46.3±2.6 79.7±4.4 <0.001
Uroflowmetry
Qmax (mL/sec) 9.3±0.7 10.6±1.0 0.290
PVR (mL) 39.3±5.8 91.1±13.7 0.001
IPSS
Total sum 19.7±1.0 19.5±1.4 0.914
Quality of life index  4.2±0.2 4.1±0.2 0.788
Operation
Operation time (min) 62.0±3.1 75.5±4.6 0.019
Energy used (kJ) 165.6±10.2 204.0±12.7 0.020
Vaporized volume (mL) 11.1±0.4 23.6±1.4 <0.001
Table 1. Patient characteristics
Qmax, maximum flow rate; PVR, post-void residual; IPSS, International
Prostate Symptom Score. 
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Fig. 2. Change in clinical parameters according to vaporized volume. (A) International Prostate Symptom Score. (B) Quality of life index.
White and black circles circle indicate the scores in the groups with the vaporized volume ≥15 g and <15 g at each month, respectively.
Gray and black bars indicate the score changes in the groups with the vaporized volume ≥15 g and <15 g at each month, respectively.
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Fig. 3. Change in clinical parameters according to vaporized volume. (A) maximum flow rate. (B) post-void residual. White and black cir-
cles circle indicate the scores in the groups with the vaporized volume ≥15 g and <15 g at each month, respectively. Gray and black
bars indicate the score changes in the groups with the vaporized volume ≥15 g and <15 g at each month, respectively.
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rate of improvement in the PVR, in the group with a greater
vaporized volume, was significantly higher compared to the
patients with a lower vaporized volume (P<0.05) (Fig. 3). 
DISCUSSION
Since the PVP creates a TUR-like cavity, its mechanism
of action is similar to that of the traditional TURP. Sulser et
al. (7) evaluated the pre-operative and post-operative prostate
volume and found that the average prostate volume changed
from 51.2 mL to 35.8 mL at three months after a PVP. Kumar
(8) and Sarica et al. (9) reported a 51% and a 53% mean dec-
rease in the prostate volume during a mean follow-up of 2.8
months and at 12 months in patients undergoing PVP. In the
present study, the pre-operative prostate volume was 61.7±
3.2 mL and at six months, the prostate volume decreased to
37.0±3.6 mL. These findings suggest that the PVP can result
in a significant prostate volume reduction.
In a non-randomized prospective study, the early outcomes
of PVP were found to be similar to those of TURP for rela-
tively small prostates (10). The first randomized comparison
of TURP with PVP also revealed that KTP laser vaporization
was equivalent to TURP in terms of decreasing IPSS and in-
creasing the Qmax, similar to the patients with relatively small
prostates (TURP 33.2 mL vs. PVP 42.4 mL) (11). However,
Hai and Malek found a 40% reduction in prostate volume
three months following a PVP but subsequent measurements
at 12 months showed an increase in the prostate volume (12).
In a multicenter study, there was an overall 29% reduction in
the prostate volume, and only a 17% reduction in the serum
PSA level at three years after the procedure (13). Te et al. (13)
suggested that the overall results achieved with a PVP are
very positive and durable up to three years; however, the clini-
cal outcome for smaller and larger prostates treated by PVP
may be disproportionate. A recent prospective randomized
study demonstrated that a significant difference in the IPSS,
Qmax and PVR values was observed during the follow-up peri-
od, and the results favored the TURP procedure for prostates
larger than 70 mL; the percentage volume reduction was sig-
nificantly higher in the TURP group (14). The percent reduc-
tion of the prostate volume was significantly higher in the
TURP group at both three (64.1% vs. 43.3%) and six months
(62.9% vs. 40.5%) and the percent reduction of the serum
PSA levels was also higher in the TURP group at three (43.7%
vs. 29.3%) and six months (44.6% vs. 31.8%). Pfitzenmaier
et al. found that there was a significant trend toward a higher
re-operation rate after a PVP in men with larger prostates (15). 
In ex vivo experiments, tissue ablation with the KTP laser
was five times slower than TURP-like tissue resection (16).
However, although tissue ablation with the KTP laser seems
to be more time-consuming than standard tissue resection,
the slower ablation performance of the KTP laser might be
compensated by its better hemostatic performance. In fact,
many investigators have suggested that the PVP is safe and
effective, with durable results for men with large volume
prostates (15, 17-19). In our series, the serum PSA and pro-
state volume at baseline, in the group with a greater vapor-
ized volume, were higher than those with a smaller vapor-
ized volume. Furthermore, the serum PSA and prostate vol-
ume remained higher in the group with a greater vaporized
volume. Nevertheless, at 6 and 12 months after surgery, the
group with a greater vaporized volume showed a greater reduc-
tion in the mean IPSS and QOL index, although the Qmax
did not increase in parallel with the decrease in the IPSS after
the PVP procedure. The time for the laser treatment was gen-
erally longer in patients with larger prostates. In addition,
there was a relationship between the amount of tissue vapor-
ization and the amount of energy delivered. These findings
suggest that the PVP is an effective method for treating BPH
caused by large prostates and that subjective improvement
after PVP may be dependent on the volume vaporized. The
determination of the appropriate treatment modality based
on the size of the prostate and other factors remains the judg-
ment of the treating surgeon.
Although sonographic estimates of prostate volume have
been widely applied, prostate volume determined by TRUS
is subject to inter-observer variation. For example, if a trans-
ducer is placed at different sites for the caudal end of the pro-
state, the prostate volume measured can be different. How-
ever, our findings were not altered by inter- or intra-observer
variation because the same examiner used the same method
for the same period of observation. 
To our knowledge, our study is the first to estimate the
volume of the prostate vaporized after a PVP and to deter-
mine their impact on the clinical outcomes. In the present
study, we added the defected volume to measure the resect-
ed volume. We learned from our patients underwent TURP
procedures that the calculated resected volume tends to be
underestimated compared to the true resected volume. Thus,
we tested new formula in this pilot study and found a very
significant correlation between the actual weight of the sur-
gical specimen and the estimated volume of the resected tis-
sue (r=0.970, P<0.001). 
In conclusion, the findings of this study suggest that the
PVP is a safe and effective method for treating BPH caused
by small or large prostates. In addition, the results suggest
that the subjective improvements noted after PVP may be
dependent on the volume of prostate tissue vaporized. How-
ever, the determination of the most appropriate treatment
modality, based on the size of the prostate and other factors,
remains the decision of the treating surgeon.
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